← All trials
NCT04573140
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Oct 26, 2021
- Primary completion
- Oct 31, 2022
- Completion date
- Oct 31, 2022
- First posted
- Oct 5, 2020
- Last posted
- Oct 28, 2021
- Enrollment
- 28
- Arms / groups
- 1 / —
- Source
- AACT · ingestion pipeline
Sponsors
- University of FloridaLead sponsor
- University of California, San FranciscoCollaborator
- University of FloridaStudy chair
- The Pacific Pediatric Neuro-Oncology ConsortiumCollaborator
- CureSearchCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.